98%
921
2 minutes
20
Cyclodextrin metal-organic frameworks (CD-MOFs) exhibit a high structural diversity, which contributes to their functional properties. In this study, we have successfully synthesized a novel type of β-cyclodextrin metal-organic framework (β-CD-POF(I)) that exhibits excellent drug adsorption capacity and enhances stability. Single-crystal X-ray diffraction analysis revealed that β-CD-POF(I) possessed the dicyclodextrin channel moieties and long-parallel tubular cavities. Compared with the reported β-CD-MOFs, the β-CD-POF(I) has a more promising drug encapsulation capability. Here, the stability of vitamin A palmitate (VAP) was effectively improved by the solvent-free method. Molecular modeling and other characterization techniques like synchrotron radiation Fourier transform infrared spectroscopy (SR-FTIR), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA), and nitrogen adsorption isotherm were applied to confirm that the VAP was successfully encapsulated into the channel formed by the dicyclodextrin pairs. Furthermore, the mechanism of stability enhancement for VAP was determined to be due to the constraint and separation effects of β-CD pairs on VAP. Therefore, β-CD-POF(I) is capable of trapping and stabilizing certain unstable drug molecules, offering benefits and application possibilities. One kind of cyclodextrin particle with characteristic shapes of dicyclodextrin channel moieties and parallel tubular cavities, which was synthesized by a facile process. Subsequently, the spatial structure and characteristics of the β-CD-POF(I) were primarily confirmed. The structure of β-CD-POF(I) was then compared to that of KOH-β-CD-MOF, and a better material for vitamin A palmitate (VAP) encapsulation was determined. VAP was successfully loaded into the particles by solvent-free method. The arrangement of spatial structure made cyclodextrin molecular cavity encapsulation in β-CD-POF(I) more stable for VAP capture than that of KOH-β-CD-MOF.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1208/s12249-023-02596-7 | DOI Listing |
Expert Rev Respir Med
September 2025
Advent Therapeutics, Inc, Doylestown, PA, USA.
Eur J Neurol
August 2025
Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
Background: Peripheral neuropathies encompass a diverse group of disorders involving peripheral nerve damage, often leading to pain, sensory disturbances, and motor impairments. The etiology is multifactorial, with trauma as a key contributor. The treatment of peripheral neuropathies includes medications targeting the nociceptive component, whereas the neuropathic component is managed with agents such as gabapentinoids or antidepressants, though their prolonged use is limited by significant side effects.
View Article and Find Full Text PDFBiomacromolecules
September 2025
Shaanxi Key Laboratory of Chemical Additives for Industry, College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi'an 710021, China.
Reactive nitrogen species (RNS)-based therapy is promising for cancer treatment, but codelivery of nitric oxide (NO) and superoxide anions (O) is hindered by their short lifetimes and uncontrolled release. In this paper, we present a light-activated supramolecular theranostic system integrating NO release with chemodynamic therapy (CDT). β-Cyclodextrin-grafted hyaluronic acid (HA-CD) and a photoresponsive NO donor (Fc-NAp-NO) self-assemble into nanocarriers, further loaded with ascorbyl palmitate (PA) to supply HO.
View Article and Find Full Text PDFFront Plant Sci
August 2025
Shandong Peanut Research Institute, Shandong Academy of Agricultural Sciences, Qingdao, China.
Background: Peanuts are a vital global crop and healthy food, valued for their nutritional and physiological benefits. Their sensory attributes and biochemical composition, which determine taste and nutritional quality, are influenced by multiple factors. Thirteen peanut genotypes were cultivated across three locations using a randomized block design.
View Article and Find Full Text PDFLangmuir
August 2025
School of Pharmacy, Henan University, Kaifeng 475004, China.
Proteolysis-targeting chimeric (PROTAC) technology represents a groundbreaking approach with immense potential for treating a wide range of diseases. However, its clinical application is often limited by challenges in solubility and permeability. Herein, we have developed an innovative three-in-one nanoparticulate therapeutic agent tailored for non-small-cell lung cancer (NSCLC).
View Article and Find Full Text PDF